Insulin-like growth factor-I and parathyroid hormone: potential new therapeutic agents for the treatment of osteoporosis

Bibliography

• MELTON LJ HI, LANE AW, COOPER C et al.: Prevalence and incidence of vertebral fracture. Osteoporosis mt. (1993) 3:113–119.
   PubMed Web of Science ®Google Scholar
• ROSEN CJ: Treatment of postmenopausal osteoporosis. In: Osteoporosis: Current Concepts. Rosen CJ (Ed.), Humana Press, Totawan, NJ (1996).
   Google Scholar
• BLACK DM, CUMMINGS SR, KARPF DB, CAULEY JA,THOMPSON ED: Randomized trial of the effect of alen-dronate on risk of fracture in women with existing fracture. Lancet (1996) 348:1535–1541.
   PubMed Web of Science ®Google Scholar
• RIGGS BL, HODGSON SF, O'FALLON VVM: Effect of fluo-ride treatment on the fracture rate in postmenopausal women with osteoporosis. New Engl. J. Med. (1990) 322:822–829.
   Google Scholar
• LUNDAY MW: Histomorphometric analysis of iliac crestbone biopsies in placebo treated vs. fluoride treated subjects. Osteoporosis Int. (1995) 5:2–17.
   Google Scholar
• PAK CYC, SAKHAEE K, ADAMS-HUET B: Treatment of postmenopausal osteoporosis with slow release so-dium fluoride. Ann. Intern. Med. (1995) 123:401–408.
   PubMed Web of Science ®Google Scholar
• RAISZ LG: Local and systemic factors in the pathogenesis of osteoporosis. New Engl. J. Med. (1988) 318:818–828.
   PubMed Web of Science ®Google Scholar
• ROSEN CJ, DONAHUE LR, HUNTER SJ: IGEs and bone: the osteoporosis connection. Proc. Soc. Exp. Biol. Med. (1994) 206:83–101.
   PubMed Web of Science ®Google Scholar
• NICHOLAS V, PREWETT A, BETTICA P et al Age-related decreases in IGF-I and TGF-I3 in femoral cortical bone from both men and women: implications for bone loss with ageing. J. Clin. Endocrinol Metab. (1994) 78:1011–1020.
   PubMed Web of Science ®Google Scholar
• ZAPF J, SCHMID C, FROESCH ER: Biological and immu- nological properties of IGF-I and IGF-IL Clin. Endocrinol Metab. (1984) 13:3–13.
   Web of Science ®Google Scholar
• BILLER BMK, SAXE V, HERZOG DB et al: Mechanisms of osteoporosis in adult and adolescent women with ano-rexia nervosa. J. Clin. Endocrinol Metab. (1989) 68:548–555.
   PubMed Web of Science ®Google Scholar
• CANALIS E, CENTRELLA M, CANALIS E: Regulatory effects of IGF-I and IGF-II on bone collagen synthesis in rat calvarial cultures. Endocrinology (1989) 124:301–306.
   PubMed Web of Science ®Google Scholar
• MACLEAN DB, KIEL DP, ROSEN CJ: Low dose Gil for frail elders stimulates bone turnover in a dose-dependent manner. J. Bone Miner. Res. (1995) 10:S458.
   PubMed Web of Science ®Google Scholar
• LINKHART TA, MOHAN S: PTH stimulates release of IGF-I and IGF-II from neonatal mouse calvaria in organ culture. Endocrinology (1989) 125:1484–1491.
   PubMed Web of Science ®Google Scholar
• CANALIS E, CENTRELLA M, BURCH W, MCCARTHY T: IGF-I mediates selective anabolic effects of PTH in bone culture. J. Clin. Invest. (1989) 83:60–65.
   PubMed Web of Science ®Google Scholar
• DONAHUE LR, BEAMER WG, ROSEN CJ: PTH improves bone density in mice with Gil and IGF-I deficiency. J Bone Miner. Res. (1995) 10 (Suppl. 1) :281.
   Google Scholar
• HODSMAN AB, FAHER LJ, OSTBYE T, ADACH1E JD, STEER BM: An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical PTH and calcitonin therapy for osteoporosis. J. Clin. Invest. (1993) 91:1138–1148.
   PubMed Web of Science ®Google Scholar
• HOCK JM, CENTRELLA M, CANALIS E: IGF-I has inde-pendent effects on bone matrix formation and cell replication. Endocrinology (1988) 122:254–260.
   PubMed Web of Science ®Google Scholar
• WATSON P, LAZOWSKI D, HAN V et al: PTH restores bone mass and enhances osteoblast IGF-I gene expression in ovariectomized rats. Bone (1995) 16:357–365.
   PubMed Web of Science ®Google Scholar
• JOHANSSON A, ROSEN CJ: The IGEs: potential anabolic agents for the skeleton. In: Anabolic Treatments for Osteoporosis. CRC Press, Toronto (1997):177–197.
   Google Scholar
• BAGI C, DE LEON E, BROMMAGE R, ROSEN D, SOMMER A: Treatment of ovariectomized rats with the complex of rh1GF-I/IGEBP-3 increases cortical and cancellous bone mass and improves structure in the femoral neck. Calcif Tissue Int. (1995) 57:40–50.
   PubMed Web of Science ®Google Scholar
• EBELING PR, JONES JD, O'FALLON WM, JANES CH, RIGGS BL: Short-term effects of recombinant human IGF-I on bone turnover in normal women. J. Clin. Endocrinol Metab. (1993) 77:1384–1391.
   PubMed Web of Science ®Google Scholar
• JOHANSSON AG, LINDH E, BLUM WF et al.: Effects of Gil and IGF4 in men with idiopathic osteoporosis. J. Clin. Endocrinol Metab. (1996) 81:44–54.
   PubMed Web of Science ®Google Scholar
• GHIRON LJ, THOMPSON JL, HOLLOWAY L et al : Effects of recombinant IGF4 and Gil on bone turnover in elderly women. J. Bone Miner. Res. (1995) 10:1844–1854.
   PubMed Web of Science ®Google Scholar
• GRINSPOON SK, BAUM HBA, PETERSON S, KLIBANSKI A:Effects of rhIGF-I administration on bone turnover during short-term fasting. J. Clin. Invest. (1995) 96:900–910.
   PubMed Web of Science ®Google Scholar
• GRINSPOON S, BAUM H, LEE K eta!: Effect of short-termrh1GF-I on bone turnover in osteopenic women with anorexia nervosa. J. Clin. Endocrinol Metab. (1996) 81:3864–3870.
   PubMed Web of Science ®Google Scholar
• BAUER F, AUB K, ALBRIGHT F: Studies of calcium andphosphorus metabolism: a study of bone trabeculae as a readily reserve supply of calcium. J. Exp. Med. (1929) 49:145–162.
   PubMedGoogle Scholar
• REEVE J, TREGAR GW, PARSON JA: Preliminary trial of low doses of human PTH peptide in treatment of osteoporosis. Calcif Tiss. Int. (1976) 21:469–477.
   Web of Science ®Google Scholar
• REEVE J, HESP R, WLLLIAMS D et al: Anabolic effects of low doses of a fragment of human PILL on the skeleton in postmenopausal osteoporosis. Lancet (1976) 1:1035–1038.
   PubMed Web of Science ®Google Scholar
• HEFTI E, TRECHSEL U, BNOJOUR JP, FLEISCH H, SCHENK R: Increase of whole body calcium and skeletal mass in normal and osteoporotic adult rats treated with para-thyroid hormone. Clin. Sci. (1982) 62:389–396.
   PubMed Web of Science ®Google Scholar
• HOCK JM, GERA U, FONSECA J, RAISZ LG: Human PTH increases bone mass in ovariectomized and orchidec-tomize d rats. Endocrinology (1988) 122:2899–2904.
   PubMed Web of Science ®Google Scholar
• LIU CC, KALU DN, SALERNO F et al.: Pre-existing bone loss associated with ovariectomy in rats is reversed by PTH. j Bone Miner. Res. (1991) 6:1071–1080.
   PubMed Web of Science ®Google Scholar
• REEVEJ, ARLOT M, BERNAT M et al.: Treatment ofosteoporosis with human PTH(1-34); a positive final tissue balance in trabecular bone. Metab. Bone Dis. Rel. Res. (1980) 2:355.
   Google Scholar
• HODSMAN AB, STEER BM, FRAHER LJ, DROST DJ: Bone densitometric and histomorphometric responses to sequential human PTH(1-38) and salmon calcitonin in osteoporotic patients. Bone Miner. (1991) 14:67–83.
   PubMedGoogle Scholar
• LINDSAY R, SOSMAN F, NIEVES J, DEMPSTER DW, SHEN V: A controlled trial of the effects of (1–34) hPTH in estrogen treated osteoporotic women. J. Bone Miner. Res. (1993) 8\(Suppl. 0:130–153.
   Google Scholar
• NEER RM, SLOVIK DM, DALY M, POTTS J: Treatment of postmenopausal osteoporosis with daily PTH plus cal-citriol. Osteoporosis Int. (1993) 1:204–205.
   Google Scholar
• FINKELSTEIN JS, KLIBANSKI A, SCHAEFER E eta!: PTH for the prevention of bone loss induced by estrogen defi-ciency. New Engl. J. Med. (1994) 331:1618–1623.
   PubMed Web of Science ®Google Scholar
• LINDSAY R, COSMAN F, SHEN V, NIEVES J, DEMPSTER DW: Bone mass increments induced by PTH treatment can be maintained by estrogen. J. Bone Miner. Res. (1995) 10\(Supp1.1):S1 200.
   Google Scholar